The antiemetic effect of granisetron in lower hemibody radiotherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/107113
Title:
The antiemetic effect of granisetron in lower hemibody radiotherapy.
Authors:
Logue, John P; Magee, Brian; Hunter, Robin D; Murdoch, R D
Abstract:
Radiotherapy-induced emesis is poorly controlled with existing antiemetics. 5-Hydroxytryptamine (5HT3) receptor antagonists are a new class of antiemetics which have been demonstrated to be effective in controlling cytotoxic-induced emesis. We have prospectively studied the antiemetic efficacy of the 5HT3 receptor antagonist granisetron in an open non-randomized efficacy and toxicity study, at two dose levels, in patients receiving lower hemibody radiotherapy for multiple bone metastases. Of the 22 patients studied, 13 patients received 20 micrograms/kg and nine patients 40 micrograms/kg of granisetron, administered as an intravenous infusion 1 h before radiotherapy. Radiotherapy was administered as a single exposure to the lower half body to a midline dose of 8 Gy. A complete response (no nausea or vomiting) was observed in 9/13 patients at the lower dose level and 6/9 patients at the higher level. No major adverse events were recorded. We conclude that granisetron is a well-tolerated and effective antiemetic agent in radiotherapy-induced emesis. Formal comparison with conventional antiemetic agents in this situation is required.
Affiliation:
Department of Radiotherapy and Oncology, Christie Hospital, Manchester, UK.
Citation:
The antiemetic effect of granisetron in lower hemibody radiotherapy. 1991, 3 (5):247-9 Clin Oncol
Journal:
Clinical Oncology
Issue Date:
Sep-1991
URI:
http://hdl.handle.net/10541/107113
DOI:
10.1016/S0936-6555(05)80871-4
PubMed ID:
1657114
Type:
Article
Language:
en
ISSN:
0936-6555
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLogue, John Pen
dc.contributor.authorMagee, Brianen
dc.contributor.authorHunter, Robin Den
dc.contributor.authorMurdoch, R Den
dc.date.accessioned2010-07-02T16:02:07Z-
dc.date.available2010-07-02T16:02:07Z-
dc.date.issued1991-09-
dc.identifier.citationThe antiemetic effect of granisetron in lower hemibody radiotherapy. 1991, 3 (5):247-9 Clin Oncolen
dc.identifier.issn0936-6555-
dc.identifier.pmid1657114-
dc.identifier.doi10.1016/S0936-6555(05)80871-4-
dc.identifier.urihttp://hdl.handle.net/10541/107113-
dc.description.abstractRadiotherapy-induced emesis is poorly controlled with existing antiemetics. 5-Hydroxytryptamine (5HT3) receptor antagonists are a new class of antiemetics which have been demonstrated to be effective in controlling cytotoxic-induced emesis. We have prospectively studied the antiemetic efficacy of the 5HT3 receptor antagonist granisetron in an open non-randomized efficacy and toxicity study, at two dose levels, in patients receiving lower hemibody radiotherapy for multiple bone metastases. Of the 22 patients studied, 13 patients received 20 micrograms/kg and nine patients 40 micrograms/kg of granisetron, administered as an intravenous infusion 1 h before radiotherapy. Radiotherapy was administered as a single exposure to the lower half body to a midline dose of 8 Gy. A complete response (no nausea or vomiting) was observed in 9/13 patients at the lower dose level and 6/9 patients at the higher level. No major adverse events were recorded. We conclude that granisetron is a well-tolerated and effective antiemetic agent in radiotherapy-induced emesis. Formal comparison with conventional antiemetic agents in this situation is required.en
dc.language.isoenen
dc.subjectBone Canceren
dc.subject.meshAged-
dc.subject.meshAntiemetics-
dc.subject.meshBone Neoplasms-
dc.subject.meshFemale-
dc.subject.meshGranisetron-
dc.subject.meshHumans-
dc.subject.meshIndazoles-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshProspective Studies-
dc.subject.meshRadiotherapy-
dc.subject.meshVomiting-
dc.titleThe antiemetic effect of granisetron in lower hemibody radiotherapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy and Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalClinical Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.